Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies

Panelists discuss how the substantial financial impact of amyloid-targeting therapies necessitates innovative approaches including value-based pricing models, outcomes-based contracts, risk-sharing arrangements between payers and manufacturers, stratified patient selection criteria, and system-level solutions to balance clinical benefit with economic sustainability for health care systems, insurers, and patients.

EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment

EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help

EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease

EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas

EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers

EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA

EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies

EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations

Now Viewing

EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies

EP: 18.Final Thoughts Alzheimer Disease Care

Related Videos

Related Content

Advertisement

May 8th 2025

Uncomplicated UTIs Tied to Greater Hospitalization Risk, Higher Health Care Costs

Brooke McCormick

A study reveals higher health care costs and resource use for uncomplicated urinary tract infections (uUTIs), emphasizing the need for improved patient management strategies.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 6th 2025

High Soluble Klotho Levels Linked to Lower CKD Prevalence in Adults With Diabetes, Hypertension

Giuliana Grossi

New research reveals how serum soluble Klotho levels relate to chronic kidney disease risk (CKD) in patients with diabetes and hypertension.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 6th 2025

Longitudinal, Relationship-Based Case Management: A Prospective Cohort Trial

Patrick Runnels, MD, MBA Ryan Muskin, MA Mark Votruba, PhD Peter J. Pronovost, MD, PhD Afua Ansah, BA James Penman, LPCC

A longitudinal, relationship-based case management approach significantly reduced health care costs and improved quality of life for Medicaid enrollees with complex needs over 1 year.

May 5th 2025

Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR

Mary Caffrey

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).

Related Content

Advertisement

May 8th 2025

Uncomplicated UTIs Tied to Greater Hospitalization Risk, Higher Health Care Costs

Brooke McCormick

A study reveals higher health care costs and resource use for uncomplicated urinary tract infections (uUTIs), emphasizing the need for improved patient management strategies.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 6th 2025

High Soluble Klotho Levels Linked to Lower CKD Prevalence in Adults With Diabetes, Hypertension

Giuliana Grossi

New research reveals how serum soluble Klotho levels relate to chronic kidney disease risk (CKD) in patients with diabetes and hypertension.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 6th 2025

Longitudinal, Relationship-Based Case Management: A Prospective Cohort Trial

Patrick Runnels, MD, MBA Ryan Muskin, MA Mark Votruba, PhD Peter J. Pronovost, MD, PhD Afua Ansah, BA James Penman, LPCC

A longitudinal, relationship-based case management approach significantly reduced health care costs and improved quality of life for Medicaid enrollees with complex needs over 1 year.

May 5th 2025

Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR

Mary Caffrey

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).